“The purpose of the course is really to bring together like-minded surgeons and physicians who are interested in robotic reconstructive surgery to really come together to not only build a network, but ...

The Novel Tracer 89Zr-TLX250 Main Discussion Topics: 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX). CAIX is an enzyme expressed on the surface of most clear cell renal cell ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Key Takeaways Sasanlimab combined with BCG improved event-free survival in high-risk NMIBC patients, particularly those with CIS and T1 tumors. Subgroup analyses showed EFS benefits across different ...

Key Takeaways The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant ...

Key Takeaways UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of ...

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments. 1 Investigators found that benefits of treatments that are observed ...

At this year’s American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada, the AUA released their new guideline on genitourinary syndrome of menopause in collaboration with the Society ...

Session ID: 2025-06-29:1a96e3213c8fbb3b6e53ba90 Player Element ID: vjs_video_3 ...

Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.

The minimally invasive incontinence treatment ProACT recently became available to patients of Allegheny Health Network (AHN) in Pittsburgh, Pennsylvania. In this interview, Kiran Sury, MD, describes ...